ERAS

Erasca Inc

ERAS, USA

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

https://www.erasca.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ERAS
stock
ERAS

Price Action Confirms Reversal in Citiport Financial Services Limited Trend - Fibonacci Retracement Levels & Free Dynamic Capital Growth Bollywood Helpline

Read more →
ERAS
stock
ERAS

Indiana energy firm puts $13M behind bid for new natural gas power Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$5

Analyst Picks

Strong Buy

5

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

2.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-8.80 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.28 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.21

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 74.96% of the total shares of Erasca Inc

1.

T. Rowe Price Investment Management,Inc.

(7.1675%)

since

2025/06/30

2.

VR Adviser, LLC

(6.295%)

since

2025/06/30

3.

BlackRock Inc

(5.3464%)

since

2025/06/30

4.

Logos Global Management LP

(5.2878%)

since

2025/06/30

5.

Suvretta Capital Management, LLC

(5.1123%)

since

2025/06/30

6.

Vanguard Group Inc

(4.4755%)

since

2025/06/30

7.

Paradigm Biocapital Advisors LP

(4.1975%)

since

2025/06/30

8.

ARCH VENTURE CORP

(3.8973%)

since

2025/06/30

9.

Siren, L.L.C.

(3.0871%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.5833%)

since

2025/07/31

11.

Vivo Capital, LLC

(2.3819%)

since

2025/06/30

12.

T. Rowe Price Small-Cap Value

(2.0949%)

since

2025/07/31

13.

5AM Venture Management, LLC

(1.9055%)

since

2025/06/30

14.

Geode Capital Management, LLC

(1.7047%)

since

2025/06/30

15.

iShares Russell 2000 ETF

(1.4896%)

since

2025/08/31

16.

Affinity Asset Advisors, LLC

(1.4403%)

since

2025/06/30

17.

State Street Corp

(1.4108%)

since

2025/06/30

18.

T. Rowe Price U.S. SC Value Eq Tr-D

(1.3914%)

since

2025/06/30

19.

Millennium Management LLC

(1.3389%)

since

2025/06/30

20.

T. Rowe Price US Small-Cap Core Equity

(1.2597%)

since

2025/06/30

21.

T. Rowe Price Small-Cap Stock

(1.2587%)

since

2025/07/31

22.

SILVERARC CAPITAL MANAGEMENT, LLC

(0.9058%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8066%)

since

2025/07/31

24.

Soleus Capital Management, L.P.

(0.7622%)

since

2025/06/30

25.

Marshall Wace Asset Management Ltd

(0.7313%)

since

2025/06/30

26.

Woodline Partners LP

(0.7313%)

since

2025/06/30

27.

T. Rowe Price Instl Small-Cap Stock

(0.6534%)

since

2025/07/31

28.

T. Rowe Price U.S. SC Core Eq Tr-D

(0.6437%)

since

2025/06/30

29.

Goldman Sachs Group Inc

(0.6415%)

since

2025/06/30

30.

Fidelity Small Cap Index

(0.6194%)

since

2025/06/30

31.

T. Rowe Price US Smlr Coms Eq A

(0.5561%)

since

2025/07/31

32.

iShares Russell 2000 Value ETF

(0.5495%)

since

2025/08/31

33.

Fidelity Extended Market Index

(0.4092%)

since

2025/07/31

34.

Schwab US Small-Cap ETF™

(0.3515%)

since

2025/08/30

35.

iShares Biotechnology ETF

(0.3384%)

since

2025/08/31

36.

Vanguard Russell 2000 ETF

(0.2886%)

since

2025/07/31

37.

JPMorgan Small Cap Value I

(0.2794%)

since

2025/07/31

38.

State St Russell Sm Cap® Indx SL Cl I

(0.229%)

since

2025/08/31

39.

Vanguard Health Care ETF

(0.1861%)

since

2025/07/31

40.

Schwab Small Cap Index

(0.1539%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.11

EPS Estimate

-0.106

EPS Difference

-0.004

Surprise Percent

-3.7736%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.